Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) shares traded down 2.4% on Monday . The company traded as low as $3.15 and last traded at $3.21, with a volume of 194,084 shares trading hands. The stock had previously closed at $3.29.

A number of research analysts have weighed in on the company. Zacks Investment Research downgraded Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. HC Wainwright assumed coverage on Anthera Pharmaceuticals in a research note on Friday, July 8th. They issued a “buy” rating and a $10.00 price target for the company. Jefferies Group restated a “buy” rating on shares of Anthera Pharmaceuticals in a research note on Thursday, June 30th. Finally, FBR & Co restated a “hold” rating on shares of Anthera Pharmaceuticals in a research note on Monday, June 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $9.58.

The company’s market capitalization is $134.85 million. The firm’s 50-day moving average price is $3.36 and its 200-day moving average price is $3.49.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.01. Analysts predict that Anthera Pharmaceuticals Inc. will post ($1.26) EPS for the current year.

Anthera Pharmaceuticals Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.